Filing Details

Accession Number:
0000899243-20-008495
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-03-16 17:17:07
Reporting Period:
2020-03-12
Accepted Time:
2020-03-16 17:17:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1672619 Imara Inc. IMRA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1572451 P David Bonita C/O Imara Inc., 116 Huntington Ave,
6Th Floor
Boston MA 02116
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-03-12 937,500 $16.00 937,500 No 4 P Indirect By OrbiMed Private Investments VII, LP
Common Stock Acquisiton 2020-03-16 1,594,902 $0.00 2,532,402 No 4 C Indirect By OrbiMed Private Investments VII, LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By OrbiMed Private Investments VII, LP
No 4 C Indirect By OrbiMed Private Investments VII, LP
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2020-03-16 10,046,294 $0.00 1,594,902 $0.00
Common Stock Stock Option (right to buy) Acquisiton 2020-03-16 15,457 $0.00 15,457 $16.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
15,457 2030-03-15 No 4 A Direct
Footnotes
  1. On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
  2. The securities are held by OrbiMed Private Investments VII, LP, or OPI VII. OrbiMed Capital GP VII LLC, or GP VII, is general partner of OPI VII, and OrbiMed Advisors LLC, or Advisors, is the managing member of GP VII. The Reporting Person is a member of Advisors. By virtue of such relationships, GP VII and Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII. Both GP VII and Advisors may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the shares held by OPI VII. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, and Sven H. Borho, each of whom disclaims beneficial ownership of the shares held by OPI VII.
  3. The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose.
  4. The option vests in three equal installments on March 16, 2021, 2022 and 2023.
  5. Pursuant to an agreement with Advisors and GP VII, the Reporting Person is obligated to transfer these securities, or the economic benefit thereof, to Advisors and GP VII, which will in turn ensure that such securities or economic benefits are provided to OPI VII.